Market Overview

Piper Jaffray, Stifel Defend Array Biopharma As Stock Falls On Profit-Taking

Piper Jaffray, Stifel Defend Array Biopharma As Stock Falls On Profit-Taking
Related ARRY
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs
The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut

The Food and Drug Administration approved Array Biopharma Inc (NASDAQ: ARRY)’s combination therapy of Mektovi and Braftovi in the treatment of BRAF-mutant melanoma on Wednesday. 

The stock, which rallied ahead of the news, subsequently plunged as investors walked with profits — but Street analysts defended Array’s upside potential.

The Ratings

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Array with a $23 price target.

Piper Jaffray analyst Edward Tenthoff maintained an Overweight rating on Array and increased the price target from $21 to $25.

The Street’s Take

The label, which to Stifel’s dismay omitted overall survival data, allows use of Mektovi-Braftovi as a first-line therapy.

The treatment demonstrates improved safety and tolerability over Novartis AG (ADR) (NYSE: NVS)’s Mekinist-Tafinlar combo, which saw a 52-percent incident rate of pyrexia against Array’s 18 percent. Array also showed superiority in the incidence of rashes, serous retinopathy and photosensitivity.

“The label's reflection of this enhanced tolerability will position Array to compete versus Novartis' industry-leading Mekinist + Tafinlar, which sold $873 million last year,” Piper Jaffray's Tenthoff said. “ ... We conservatively project uptake in the second-line setting, but could see MEKTOVI + BRAFTOVI take some first-line share from checkpoint inhibitor immunotherapy.”

With partners having submitted out-of-U.S. filings and won approval in Japan, Piper Jaffray forecast a $1-billion global market opportunity, with initial U.S. sales of $17.2 million in 2018, $71.5 million in 2019 and $297 million in 2020.

Stifel anticipates 2019 and 2020 sales of $69 million and $185 million, respectively.

Price Action

At the time of publication Thursday, Array was trading down 3.75 percent off the open at $16.94. 

Related Links:

Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street

The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs

Latest Ratings for ARRY

Jun 2018Wells FargoMaintainsOutperformOutperform
Jun 2018Cantor FitzgeraldMaintainsOverweightOverweight
Feb 2018Leerink SwannMaintainsOutperformOutperform

View More Analyst Ratings for ARRY
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Price Target Reiteration Top Stories Analyst Ratings Trading Ideas General Best of Benzinga


Related Articles (ARRY + NVS)

View Comments and Join the Discussion!

Latest Ratings

TVPTImperial CapitalDowngrades15.8
ACORGoldman SachsDowngrades10.0
BCOVB. Riley FBRUpgrades12.0
CAMPFirst AnalysisDowngrades22.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Leveraged Mexico ETF Garners Interest Ahead Of Rate Hike

The Pullback In Twilio Creates A 'Favorable Entry Point,' Argus Says In Upgrade